393 related articles for article (PubMed ID: 1830596)
1. Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype x anti-CD3).
Demanet C; Brissinck J; Van Mechelen M; Leo O; Thielemans K
J Immunol; 1991 Aug; 147(3):1091-7. PubMed ID: 1830596
[TBL] [Abstract][Full Text] [Related]
2. Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma.
Weiner GJ; Hillstrom JR
J Immunol; 1991 Dec; 147(11):4035-44. PubMed ID: 1834746
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy with bispecific antibodies.
Thielemans KM
Verh K Acad Geneeskd Belg; 1995; 57(3):229-47; discussion 247-8. PubMed ID: 7483816
[TBL] [Abstract][Full Text] [Related]
4. Bispecific antibody therapy of two murine B-cell lymphomas.
Demanet C; Brissinck J; Moser M; Leo O; Thielemans K
Int J Cancer Suppl; 1992; 7():67-8. PubMed ID: 1428409
[TBL] [Abstract][Full Text] [Related]
5. Treatment of mice bearing BCL1 lymphoma with bispecific antibodies.
Brissinck J; Demanet C; Moser M; Leo O; Thielemans K
J Immunol; 1991 Dec; 147(11):4019-26. PubMed ID: 1940384
[TBL] [Abstract][Full Text] [Related]
6. Role of T-cell subsets in the bispecific antibody (anti-idiotype x anti-CD3) treatment of the BCL1 lymphoma.
Demanet C; Brissinck J; Leo O; Moser M; Thielemans K
Cancer Res; 1994 Jun; 54(11):2973-8. PubMed ID: 8187084
[TBL] [Abstract][Full Text] [Related]
7. The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy.
Weiner GJ; Kostelny SA; Hillstrom JR; Cole MS; Link BK; Wang SL; Tso JY
J Immunol; 1994 Mar; 152(5):2385-92. PubMed ID: 8133049
[TBL] [Abstract][Full Text] [Related]
8. Idiotype vaccination strategies against a murine B-cell lymphoma: dendritic cells loaded with idiotype and bispecific idiotype x anti-class II antibodies can protect against tumor growth.
Bohlen H; Thielemanns K; Tesch H; Engert A; Wolf HJ; van Camp B; Urbain J; Diehl V
Cytokines Mol Ther; 1996 Dec; 2(4):231-8. PubMed ID: 9384709
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibodies to murine CD3 epsilon define distinct epitopes, one of which may interact with CD4 during T cell activation.
Portoles P; Rojo J; Golby A; Bonneville M; Gromkowski S; Greenbaum L; Janeway CA; Murphy DB; Bottomly K
J Immunol; 1989 Jun; 142(12):4169-75. PubMed ID: 2470817
[TBL] [Abstract][Full Text] [Related]
10. Activation of resting T cells against the CA 72-4 tumor antigen with an anti-CD3/CA 72-4 bispecific antibody in combination with a costimulatory anti-CD28 antibody.
Hombach A; Mathas S; Jensen M; Tillmann T; Menges M; Diehl V; Kruis W; Pohl C
Anticancer Res; 1997; 17(3C):2025-32. PubMed ID: 9216660
[TBL] [Abstract][Full Text] [Related]
11. Anti-CD3 + IL-2-stimulated murine killer cells. In vitro generation and in vivo antitumor activity.
Anderson PM; Blazar BR; Bach FH; Ochoa AC
J Immunol; 1989 Feb; 142(4):1383-94. PubMed ID: 2521662
[TBL] [Abstract][Full Text] [Related]
12. Characterization of IgG FcR-mediated proliferation of human T cells induced by mouse and human anti-CD3 monoclonal antibodies. Identification of a functional polymorphism to human IgG2 anti-CD3.
Parren PW; Warmerdam PA; Boeije LC; Capel PJ; van de Winkel JG; Aarden LA
J Immunol; 1992 Feb; 148(3):695-701. PubMed ID: 1530954
[TBL] [Abstract][Full Text] [Related]
13. Anti-CD3 monoclonal antibody therapy. An approach toward optimization by in vitro analysis of new anti-CD3 antibodies.
Woodle ES; Thistlethwaite JR; Jolliffe LK; Fucello AJ; Stuart FP; Bluestone JA
Transplantation; 1991 Aug; 52(2):361-8. PubMed ID: 1714644
[TBL] [Abstract][Full Text] [Related]
14. Induction of T cell proliferation with anti-CD3 switch-variant monoclonal antibodies: effects of heavy chain isotype in monocyte-dependent systems.
Van Lier RA; Boot JH; De Groot ER; Aarden LA
Eur J Immunol; 1987 Nov; 17(11):1599-604. PubMed ID: 2960543
[TBL] [Abstract][Full Text] [Related]
15. Expression of a 33-kDa antigen Tm 1 on lymphocyte surface after modulation of cell surface antigens by IgM monoclonal antibody.
Hara T; Jung LK; Fu SM
J Immunol; 1988 Feb; 140(4):1028-33. PubMed ID: 2963858
[TBL] [Abstract][Full Text] [Related]
16. In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-CD3 x anti-idiotype) induces long-term survival in the murine BCL1 lymphoma model.
De Jonge J; Heirman C; de Veerman M; Van Meirvenne S; Moser M; Leo O; Thielemans K
J Immunol; 1998 Aug; 161(3):1454-61. PubMed ID: 9686611
[TBL] [Abstract][Full Text] [Related]
17. The targeting of CD4+ T lymphocytes to a B cell lymphoma. A comparison of anti-CD3-anti-idiotype antibody conjugates and antigen-anti-idiotype antibody conjugates.
Gravelle M; Ochi A
J Immunol; 1989 Jun; 142(11):4079-84. PubMed ID: 2523940
[TBL] [Abstract][Full Text] [Related]
18. Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies.
Bohlen H; Manzke O; Patel B; Moldenhauer G; Dörken B; von Fliedner V; Diehl V; Tesch H
Cancer Res; 1993 Sep; 53(18):4310-4. PubMed ID: 7689932
[TBL] [Abstract][Full Text] [Related]
19. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
Katzenwadel A; Schleer H; Gierschner D; Wetterauer U; Elsässer-Beile U
Anticancer Res; 2000; 20(3A):1551-5. PubMed ID: 10928069
[TBL] [Abstract][Full Text] [Related]
20. A polymorphic Fc receptor for mouse IgG2b on human B cells and monocytes.
Holtrop S; Rijke-Schilder GP; Koene RA; Tax WJ
Immunology; 1991 Dec; 74(4):613-20. PubMed ID: 1838352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
